SNCE Science 37
WatchlistScience 37 News
Science 37 To Carry Out 1-for-20 Reverse Stock Split On December 8th, 2023
December 6th - $Science 37(SNCE.US)$ is about to implement a 1-for-20 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from December 8th, 2023.$Science 37(SNCE.US
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersAllarity Therapeutics (NASDAQ:ALLR) shares rose 44.0% to $0.86 during Tuesday's pre-market session. The company's market cap stands at $3.9 million. Sonoma Pharmaceuticals (NASDAQ:SNOA) stock r
Science 37 Down 12%, Will Effect 1-for-20 Reverse Stock Split to Regain Nasdaq Compliance
Science 37 Holdings, Inc. Announces 1-for-20 Reverse Stock Split Effective December 8, 2023
RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE) ("Science 37" or the "Company"), the clinical research industry-leading Metasite, announced today that it
Science 37 Holdings, Inc. (NASDAQ:SNCE) Q3 2023 Earnings Call Transcript
It's Down 28% But Science 37 Holdings, Inc. (NASDAQ:SNCE) Could Be Riskier Than It Looks
Q3 2023 Science 37 Holdings Inc Earnings Call
Science 37's Stock: A Buy Rating Despite Short-Term Setbacks, Anticipating Long-Term Financial Stability
Analysts' Top Healthcare Picks: Science 37 (SNCE), Guardant Health (GH)
Science 37 Reports Mixed Q3 Earnings; Initiates Q4 and Updates FY23 Outlook
Science 37 Sees FY23 Adjusted EBITDA Loss Of Approximately $(32.5)M Versus Prior Guidance Of Approximately $(35.0)M
Science 37 Sees FY23 Adjusted EBITDA Loss Of Approximately $(32.5)M Versus Prior Guidance Of Approximately $(35.0)M
Science 37 Is Providing Updated Revenue Guidance Of $58M-$59M Versus Prior Outlook Of Approximately $60M Versus Consensus Of $60.01M
Science 37 Is Providing Updated Revenue Guidance Of $58M-$59M Versus Prior Outlook Of Approximately $60M Versus Consensus Of $60.01M
Science 37 Hldgs Q3 Adjusted EPS $(0.05) Beats $(0.07) Estimate, Sales $14.89M Beat $14.83M Estimate
Science 37 Hldgs (NASDAQ:SNCE) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 70.59 percent increase over losses of $(0
Earnings Flash (SNCE) SCIENCE 37 Posts Q3 Revenue $14.9M, Vs. Street Est of $14.8M
06:02 AM EST, 11/07/2023 (MT Newswires) -- Earnings Flash (SNCE) SCIENCE 37 Posts Q3 Revenue $14.9M, vs. Street Est of $14.8M
Science 37 to Report Third Quarter 2023 Financial Results on November 7, 2023
RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite today announced it will report third quarter 2023 financial results prior
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA) and Science 37 (SNCE)
Science 37 Recognized in the Gartner Hype Cycle for Life Science Clinical Development, 2023
RESEARCH TRIANGLE PARK, N.C., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Science 37 announced today that it has been recognized in the Gartner Hype Cycle for Life Science Clinical Development, 2023. As stat
Science 37 Named Market Leader for Global Decentralized Clinical Trials by Frost & Sullivan
RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite, today announced that it has been honored w
Science 37 to Participate in H.C. Wainwright 25th Annual Global Investment Conference
RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite, today announced the company will be participating in the upc
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersNovo Integrated Sciences (NASDAQ:NVOS) stock increased by 109.0% to $0.24 during Wednesday's pre-market session. The market value of their outstanding shares is at $35.9 million. MSP Recovery (